Skip to main content
HRMY logo

HRMY · Harmony Biosciences Holdings, Inc. · Documents

Track HRMY — free
Market Cap
$1.94B
Shares
58.72M
Volume · Nov 17 607.35K Avg daily vol (3M) 1M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $868.45M up 21.5% 10-K filed Feb 24, 2026 Quarterly report FY2026 Q3 Revenue $268.92M up 12.3% 10-Q filed Nov 4, 2026 Latest results WAKIX revenue reached $268.9 million as guidance held 8-K filed Nov 4, 2026 Earnings call Q3 2026 earnings call Held Nov 4, 2026
2026
Nov 4
Earnings call
WACIX growth and BP-205 data support revenue outlook

Harmony Biosciences reported Q3 WACIX net revenue of $269 million and reiterated 2026 guidance of $1 to $1.04 billion. BP-205 showed an approximately 29-hour effective half-life, and Peter Anastasiou will become CEO on January 1, 2027.

4 source passages
For the third quarter of 2026, we reported net revenue of $269 million compared to $239 million in the prior year quarter. And we remain on track to achieve our full-year guidance of $1 to $1.04 billion. The mean effective half-life was approximately 29 hours, not meaningfully different from the SAD study, and it supports one steady dosing and the potential for durable efficacy throughout the day and potentially with no troublesome insomnia as evidenced by the tolerability profile of BP-205 from the SAD and the MAD data. I will be stepping down at the end of the year, and Peter Anastasiou, our Senior Executive Vice President and Chief Operating Officer, will succeed me as President and Chief Executive Officer, effective January 1, 2027. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Net product revenue rose 12.3%; Pitolisant GR accepted for review

Harmony’s net product revenue increased $29.5 million, or 12.3%, for the three months ended September 30, 2026. Pitolisant GR received full FDA review with a target PDUFA date of April 1, 2027.

Revenue $268.92M ▲ 12.3% Net income $48.2M ▼ 5.2% Diluted EPS $0.81 ▼ 6.9%
Read from the MD&A section
3 source passages
At Harmony, we are cultivating a differentiated neuroscience company, rooted in innovation and driven by a commitment to addressing the unmet needs of patients living with neurological diseases. Net product revenue increased by $29.5 million, or 12.3%, for the three months ended September 30, 2026, and increased by $120.9 million, or 19.4%, for the nine months ended September 30, 2026, compared to the same periods in 2025. In June 2026, we submitted a New Drug Application (“NDA”) for Pitolisant GR to the FDA, which was subsequently accepted for full review with a target Prescription Drug User Fee Act (“PDUFA”) date of April 1, 2027. Open the document at this passage
Nov 4
Current report 8-K
WAKIX revenue reached $268.9 million as guidance held

Harmony Biosciences reported WAKIX net revenue of $268.9 million for the quarter ended September 30, 2026 and reiterated 2026 guidance of $1.0 billion to $1.04 billion. BP-205 preliminary results were favorable, and Peter Anastasiou will become CEO on January 1, 2027.

Financial results, Regulation FD disclosure
4 source passages
WAKIX net revenue for the quarter ended September 30, 2026, was $268.9 million, driven by strong patient demand: Based on our results for the first nine months of 2026, WAKIX remains on track to achieve full-year net revenue of $1.0 billion to $1.04 billion. The encouraging preliminary results from the MAD study with BP-205, following 14 days of repeated once-daily dosing, reinforce the favorable safety, tolerability and pharmacokinetic profile observed in the single-ascending dose (SAD) portion of the study. Peter Anastasiou, Senior Executive Vice President and Chief Operating Officer, will become President and Chief Executive Officer effective January 1, 2027, succeeding Jeffrey Dayno, MD, who will retire on December 31, 2026. Open the document at this passage
Oct 30
Current report 8-K/A Events of Oct 12
CEO succession terms include severance and equity awards

Harmony Biosciences Holdings, Inc. said Jeffrey M. Dayno will retire as CEO effective December 31, 2026, receive $770,000, and be succeeded by Peter Anastasiou effective January 1, 2027. Anastasiou’s salary will be $725,000, with equity awards of $1,750,000 and $750,000.

Director or officer change, or executive pay Read from the first part of this long document
5 source passages
On October 12, 2026, the Company announced that Jeffrey M. Dayno, M.D., as part of a leadership succession plan, will be retiring as the Company’s President and Chief Executive Officer and stepping down as a Class I director of the Company’s Board of Directors (the “Board”), in each case, effective as of December 31, 2026, at 11:59 p.m. Eastern Time (the “Resignation Effective Date”), and will serve as a non-executive advisor to the Company through January 2028. On October 12, 2026, the Company also announced that Peter Anastasiou, the Company’s current Senior Executive Vice President, Chief Operating Officer, has been appointed by the Board to serve as President and Chief Executive Officer of the Company and as a Class I director of the Company’s Board, each effective as of January 1, 2027, at 12:00 a.m. Eastern Time (the “Appointment Effective Date”) to fill the vacancy resulting from Dr. Dayno’s resignation. The Company shall pay to Executive an amount equal to $770,000, representing 12 months of Executive’s base salary as in effect on the Separation Date, payable pursuant to Section 3.03(a) of the Employment Agreement; Mr. Anastasiou’s annual base salary will be $725,000, effective as of the Appointment Effective Date. Within 30 days of the Appointment Effective Date, Mr. Anastasiou will be eligible to receive an option award and an award of restricted stock units with an aggregate grant date fair value of $1,750,000 and $750,000, respectively. Open the document at this passage
Oct 13
Current report 8-K Events of Oct 12
Director or officer change, or executive pay, Regulation FD disclosure

Harmony Biosciences Holdings, Inc. appointed Peter Anastasiou CEO and director effective January 1, 2027; Jeffrey M. Dayno, M.D., will retire and leave the board on December 31, 2026. Full-year 2026 WAKIX net revenue guidance remains $1.0 billion to $1.04 billion.

Aug 4
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $261.28M ▲ 30.3% Net income $75.43M ▲ 89.6% Diluted EPS $1.28 ▲ 88.2%
May 7
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $215.39M ▲ 16.6% Net income $32.49M ▼ 28.7% Diluted EPS $0.55 ▼ 29.5%
Apr 3
Proxy statement DEF 14A Meeting May 14, 2026
Proxy statement AI summary on its way
Feb 24
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $868.45M ▲ 21.5% Net income $158.69M ▲ 9.1% Diluted EPS $2.71 ▲ 8.0%
2025
Nov 4
Quarterly report 10-Q FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Revenue $239.46M ▲ 28.7% Net income $50.87M ▲ 10.4% Diluted EPS $0.87 ▲ 10.1%
Aug 5
Quarterly report 10-Q FY2025 Q2, ended Jun 30
Quarterly report for FY2025 Q2
Revenue $200.49M ▲ 16.0% Net income $39.78M ▲ 243.2% Diluted EPS $0.68 ▲ 240.0%
May 6
Quarterly report 10-Q FY2025 Q1, ended Mar 31
Quarterly report for FY2025 Q1
Revenue $184.73M ▲ 19.5% Net income $45.56M ▲ 18.9% Diluted EPS $0.78 ▲ 16.4%
Feb 25
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $714.73M ▲ 22.8% Net income $145.49M ▲ 12.9% Diluted EPS $2.51 ▲ 17.8%
2024
Showing 1–50 of 160 documents
Key facts CIK 1802665 CUSIP 413197104 13F (30d) 362 filings 343 filers Visit website Investor relations